Belshe, R B <br/><br/>
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.  [electronic resource] 

 -  The Journal of infectious diseases  May 2001 
 - 1343-52 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0022-1899 
<br/><br/><label>Standard No.: </label>10.1086/319863  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>AIDS Vaccines--genetics<br/>Adolescent<br/>Adult<br/>Avipoxvirus--immunology<br/>CD8-Positive T-Lymphocytes--immunology<br/>Double-Blind Method<br/>Female<br/>Genetic Vectors<br/>HIV Envelope Protein gp120--genetics<br/>HIV Infections--prevention & control<br/>HIV Protease--genetics<br/>HIV-1--immunology<br/>Humans<br/>Immunization Schedule<br/>Immunization, Secondary<br/>Male<br/>Middle Aged<br/>Risk Factors<br/>Safety<br/>T-Lymphocytes, Cytotoxic--immunology<br/>Vaccines, Attenuated<br/>Vaccines, Synthetic